Method
Level · gp.fundamentals.debt_to_revenue
Raw value 759.36% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTPrestige Consumer Healthcare Inc.'s latest supported as-filed period reports revenue of $265.7M; gross margin moved 498 basis points lower on the same comparison basis. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 759.36% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 1.39% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 26.64% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 6.48% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 71.59% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 51.25% · CORE
Level · gp.fundamentals.operating_margin
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Capex / revenue changed +106 basis points from the comparable as-filed period.
Capital expenditure changed +341.9% from the comparable as-filed period. The change ranks at the 100th percentile of 6 prior comparable changes.
Cash & equivalents changed -36.1% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
PBH · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001295947-26-000049SEC ↗10-QAug 6, 2026Period Jun 30, 20260001295947-26-000042SEC ↗8-KAug 6, 2026Period Aug 6, 20260001295947-26-000040SEC ↗4Aug 5, 2026Period Aug 4, 20260001104659-26-091086SEC ↗4Aug 5, 2026Period Aug 4, 20260001104659-26-091084SEC ↗4Aug 5, 2026Period Aug 4, 20260001104659-26-091082SEC ↗4Aug 5, 2026Period Aug 4, 20260001104659-26-091081SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 4, 2026Filed Aug 5, 2026 | ZIER DAWN M.Director | Grant Or AwardDirect | 2,981 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 19.77% · CORE
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 1.50% · OPTIONAL
Debt changed -98.9% from the comparable as-filed period.
Free-cash-flow proxy changed -14.2% from the comparable as-filed period. The change ranks at the 33th percentile of 6 prior comparable changes.
Gross margin changed -498 basis points from the comparable as-filed period.
Gross profit changed -3.0% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001104659-26-091079